Trial Profile
Cediranib In Recurrent Cervical Cancer - A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2022
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CIRCCa
- 13 Apr 2019 Results identifying a minimally-invasive biomarker predicting benefit from cediranib pre-treatment published in the British Journal of Clinical Pharmacology.
- 13 Oct 2015 Results published in the Lancet Oncology
- 25 Aug 2012 Accrual to date is 86% according to United Kingdom Clinical Research Network.